50. Dermatomyositis Clinical trials / Disease details


Clinical trials : 194 Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02245841
(ClinicalTrials.gov)
June 15, 201511/9/2014Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of DermatomyositisEfficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of DermatomyositisDermatomyositis;Juvenile DermatomyositisDrug: H.P. Acthar GelThe Cleveland ClinicMallinckrodtCompleted18 YearsN/AAll15Phase 4United States
2NCT01906372
(ClinicalTrials.gov)
September 20135/7/2013Acthar in Treatment of Refractory Dermatomyositis and PolymyositisOpen Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or PolymyositisDermatomyositis;PolymyositisDrug: Adrenocorticotropic Hormone GelRohit Aggarwal, MDMallinckrodtCompleted18 YearsN/AAll12Phase 2United States
3NCT01637064
(ClinicalTrials.gov)
April 20136/7/2012Dermatomyositis and Polymyositis RegistryActhar Dermatomyositis and Polymyositis TreatmentDermatomyositis;PolymyositisDrug: ActharPhoenix Neurological Associates, LTDNULLEnrolling by invitation18 Years85 YearsBoth100N/AUnited States